Received Apr 15, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
received Engerix B late second dose; This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too long in an unspecified number of patients who received HBV (Engerix B) for prophylaxis. Previously administered products included Engerix B (received 1st dose in October 2024). In APR-2025, the patient received the 2nd dose of Engerix B. In APR-2025, an unknown time after receiving Engerix B, the patient experienced drug dose administration interval too long (Verbatim: received Engerix B late second dose). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK receipt date: 08-APR-2025 The wellness center supervisor called to report multiple patients received late second doses for Engerix-B. The reporter stated that they had individuals that got the vaccine in October 2024, and they were getting their second dose in April 2025, six months later which led to, drug dose administration interval too long. We are probably giving about sixty of these vaccines in the last few months, not all of them were late second doses. Somehow, had about five or six people slip through the cracks in October and they did not know how that happened, but it happened. The reporter mentioned that when asked about patients details information was declined. Patient details, vaccination dates or more specific information was asked but declined during the call.